Insurers are pressing for changes to the accelerated approval pathway in the wake of research that shows accelerated approval drugs comprise a growing share of Medicare drug spending. America’s Health Insurance Plans says lawmakers should create more enforcement controls for the accelerated approval pathway as Congress considers renewing the Cures Act . AHIP didn’t specify the enforcement controls it seeks. For breakthrough drugs, the recently unveiled Cures 2.0 bill primarily is concerned with improving communication between FDA and CMS. The...